Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis

[1]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Yong Wang,et al.  Long non-coding RNA ZNF674-AS1 antagonizes oxaliplatin resistance of gastric cancer via regulating EZH2-mediated methylation of CHST7 , 2022, Aging.

[3]  Xinxiang Li,et al.  Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids , 2021, Journal of experimental & clinical cancer research : CR.

[4]  Q. Xie,et al.  uc.77- Downregulation Promotes Colorectal Cancer Cell Proliferation by Inhibiting FBXW8-Mediated CDK4 Protein Degradation , 2021, Frontiers in Oncology.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  Liming Gao,et al.  Long non-coding RNA LINC00982 up-regulates CTSF expression to inhibit gastric cancer progression via the transcription factor HEY1. , 2020, American journal of physiology. Gastrointestinal and liver physiology.

[7]  Likun Zhou,et al.  LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer , 2020, Molecular therapy. Nucleic acids.

[8]  Xiaokun Zhao,et al.  LncRNA ZNF503-AS1 acts as a tumor suppressor in bladder cancer by up-regulating Ca2+ concentration via transcription factor GATA6 , 2020, Cellular Oncology.

[9]  Yuliang Zhang,et al.  Long non-coding RNA MALAT1 regulates oxaliplatin-resistance via miR-324-3p/ADAM17 axis in colorectal cancer cells , 2020, Cancer cell international.

[10]  H. Yao,et al.  Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade. , 2020, Cell reports.

[11]  Haowen Zhang,et al.  Long non-coding RNAs: Key regulators in oxaliplatin resistance of colorectal cancer. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  G. Bossi,et al.  The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments , 2020, International journal of molecular sciences.

[13]  Jianjun Chen,et al.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. , 2020, Cancer cell.

[14]  B. Schulman,et al.  Molecular glue concept solidifies , 2019, Nature Chemical Biology.

[15]  Wei Liu,et al.  Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[16]  M. Ye,et al.  Downregulation of long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  Yong Jiang,et al.  Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications , 2019, Molecular Cancer.

[18]  G. Sun,et al.  Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[19]  J. Mendell,et al.  Functional Classification and Experimental Dissection of Long Noncoding RNAs , 2018, Cell.

[20]  H. Kovacic,et al.  Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway , 2017, Oncotarget.

[21]  B. Bastian,et al.  RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. , 2017, Cancer cell.

[22]  D. Yan,et al.  Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  T. Ørntoft,et al.  miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells , 2016, Nature Communications.

[24]  T. Hothorn,et al.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[25]  J. Stenvang,et al.  Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance , 2015, Molecular oncology.

[26]  Z. Nagy,et al.  Function of RasGRP3 in the formation and progression of human breast cancer , 2014, Molecular Cancer.

[27]  Zhi-Ren Liu,et al.  Phosphorylation of P68 RNA Helicase by P38 MAP kinase contributes to colon cancer cells apoptosis induced by oxaliplatin , 2012, BMC Cell Biology.

[28]  D. Sargent,et al.  Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. , 2009, Clinical colorectal cancer.

[29]  Ling Xia,et al.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.

[30]  Yong Zhang,et al.  CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine , 2007, Nucleic Acids Res..

[31]  E. Van Cutsem,et al.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[33]  M. Matsuda,et al.  CalDAG-GEFIII Activation of Ras, R-Ras, and Rap1* , 2000, The Journal of Biological Chemistry.

[34]  J. Stone,et al.  RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs. , 1998, Science.

[35]  E. Raymond,et al.  Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.

[36]  Huifang Huang,et al.  Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link , 1995, Science.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..